

SWOG NCORP Research Base Clinical Trials Workshop

Wednesday, October 19, 2022, 12:30 to 4:00 pm CT

Agenda

Welcome and NCORP Research Base Overview

Sam Dzingle, SWOG Statistics and Data Management Center

NCORP Research Areas

Clinical Trials

SWOG NCORP RESEARCH BASE: Progress and Future Opportunities

Dawn Hershman, MD, MS, FASCO, SWOG Cancer Research Network Vice-Chair

Use of Patient-Reported Outcomes in SWOG Trials: Past, Present, and Future

Presenter: Joseph Unger, PhD, SWOG Statistics and Data Management Center

Panelists: Mathew Eng, PharmD, SWOG Statistics and Data Management Center

Dawn Hershman, MD, MS, FASCO, Columbia University

Alison Gnerre, RN, St. Joseph Hospital

Riha Vaidya, PhD, SWOG Statistics and Data Management Center

A Walk on the Wild Side

Evonne Lackey, CCRP, Pacific Cancer Research Consortium NCORP

NCORP Briefs: Trial Spotlight from the Data Coordinators

SWOG Statistics and Data Management Center

Facilitator: Kimberly Carvalho

Panelists: Sam Dzingle

Mathew Eng, PharmD

Manny Kharbanda

Diane Liggett, CCRP

Roxanne Topacio, CCRP

Cancer Disparities

NCORP Disparities Integration Efforts – Learning Within and Across the Network

Brenda Adjei, MPA, EdD, NCI Office of the Associate Director of the Healthcare Delivery Research Program (HDRP)

Cancer Care Delivery Research

Tracing TrACER: Lessons Learned from SWOG's First Large Pragmatic Trial in Cancer Care Delivery

Scott Ramsey, MD, PhD, SWOG Cancer Care Delivery Research Committee Co-Chair

Closing Remarks



SWOG NCORP Research Base Clinical Trials Virtual Workshop

Wednesday, October 19, 2022, 12:30 – 4:00 pm CT

Certification of Attendance:

I certify that I attended _____ hours of this meeting. The topics of the meeting contribute to the education and professional advancement in clinical research.

Attendee Signature _____ Date _____

Program Director, SWOG NCORP Data Management:

Monica Yee, CCRP — monicay@crab.org



SWOG NCORP Research Base Clinical Trials Active Studies

Study #	Study Title	Activation	Accrual	Participating Sites
Cancer Care Delivery Research Committee				
S1703	Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) versus Usual Care in Patients with Metastatic Hormone Receptor Positive HER-2 Negative Breast Cancer	July 2018	236 of 1320 18%	NCTN and NCORP
S1912CD	A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery of a Proactive Financial Navigation Intervention (CREDIT)	July 2021	46 of 536 9%	NCORP Only
S2108CD	A Cluster Randomized Trial Comparing An Educationally Enhanced Genomic Tumor Board (EGTB) Intervention to Usual Practice to Increase Evidence-Based Genome-Informed Therapy	August 2022	0 of 1182 0%	NCORP Only
Cancer Survivorship Committee				
S1501	Prospective Evaluation of Carvedilol vs No treatment in Prevention of Cardiac Dysfunction in Patients with Metastatic HER-2+ Breast Cancer	September 2017	284 of 817 35%	NCTN and NCORP
Palliative and End of Life Care Committee				
	Concepts in development			
Prevention and Epidemiology Committee				
S0820	A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)	March 2013	342 of 389 88%	NCTN and NCORP
S1823	A Prospective Observational Cohort Study to Assess miRNA371 for Outcome Prediction in Patients with Early Stage Germ Cell Tumors	June 2020	594 of 956 62%	NCTN and NCORP
S1904	Cluster Randomized Controlled Trial of Patient and Provider Decision Support to Increase Chemoprevention Informed Choice Among Women with Atypical Hyperplasia or Lobular Carcinoma In Situ - Making Informed Choices on Incorporating Chemoprevention into Care (MiCHOICE)	September 2020	217 of 415 52%	Limited institution
Symptom Control and Quality of Life Committee				
S1600	A Randomized Phase III Double-Blind Clinical Trial Evaluating the Effect of Immune-Enhancing Nutrition on Radical Cystectomy Outcomes	February 2019	150 of 200 75%	NCTN and NCORP
S2013	Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study	August 2021	456 of 2062 22%	NCTN and NCORP

Questions? Contact cancercontrolquestion@crab.org

SWOG NCORP Research Base Clinical Trials Activating in the Next Year

Study #	Study Title	Estimated Activation	Accrual Goal	Participating Sites
Cancer Survivorship Committee				
S2204	Randomized Phase III Trial of a Perioperative Physical Activity Intervention in Older Adults with Lung Cancer and their Family Caregivers	Summer 2023	382	NCTN and NCORP
Symptom Control and Quality of Life Committee				
S2010	A Randomized Phase III Trial Comparing Active Symptom Monitoring Plus Patient Education Versus Patient Education Alone To Improve Persistence With Endocrine Therapy in Young Women With Stage I-III Breast Cancer (ASPEN)	Fall 2022	540	NCTN and NCORP
S2205	ICE COMPRESS: Randomized Trial of Limb Cryocompression Versus Continuous Compression Versus Low Cyclic Compression for the Prevention of Taxane-Induced Peripheral Neuropathy	Winter 2023	777	Limited Institution (Site applications being processed)

SWOG NCORP Research Base Clinical Trials Completed Accrual in the Past Year

Study #	Study Title	Activation/ Closure	Accrual	Participating Sites
Palliative and End of Life Care Committee				
S1820	A Randomized Trial of the Altering Intake, Managing Symptoms Intervention for Bowel Dysfunction in Rectal Cancer Survivors Compared to a Healthy Living Education Control: A Feasibility and Preliminary Efficacy Study (AIMS-RC)	December 2019 Closed April 2022	95 of 94 100%	NCTN and NCORP
Symptom Control and Quality of Life Committee				
S1614	Randomized Trial of Prophylactic Antiviral Therapy in Patients with Current or Past Hepatitis B Virus (HBV) Infection Receiving Cytotoxic Therapy for Solid Tumors	July 2021 Temp Closure September 2022	4 of 444	NCTN and NCORP
S1714	A Prospective Observational Cohort Study to Develop a Predictive Model of Taxane-Induced Peripheral Neuropathy in Cancer Patients	March 2019 Closed November 2021	1336 of 1336 100%	NCTN and NCORP

Questions? Contact cancercontrolquestion@crab.org